Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01545050 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
A Phase 2 study, sponsored by CSL Behring.
- Terminated
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT01545050: Clinical Trial Phase 2 study, sponsored by CSL Behring.
NCT01545050 is a Phase 2 study that was terminated before completion, run by CSL Behring. The registered enrollment target is 72 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (46% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01545050, a Phase 2 study, was terminated before completion, sponsored by CSL Behring.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with moderate to severe Crohn's disease and who have had an insufficient response to conventional therapy or have failed Anti-Tumor Necrosis Factor (anti-TNF) therapy.
Primary Outcome
CDAI scores range from 0 to 600. A score of less than 150 corresponds to relative disease quiescence (remission); 150 to 219, mildly active disease; 220 to 450, moderately active disease; and greater than 450, severe disease. A decrease in greater than 100 points indicates a clinically significant improvement in disease activity
Interventions
- BIOLOGICAL BMS-945429
- BIOLOGICAL Placebo matching with BMS-945429
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2012-06 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Why NCT01545050 stopped before completion
NCT01545050 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (46% lower).
The record links to 0 conditions, and to 2 interventions - of which BMS-945429 is the first listed.
NCT01545050 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01545050 about?
NCT01545050 is a clinical study titled "Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease". The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with moderate to severe Crohn's disease and who have had an insufficient response to conventional therapy or have failed Anti-Tumor Necrosis Factor (anti-TNF) therapy.
What is the current status of trial NCT01545050?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2012-06. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01545050?
The interventions under investigation include: BMS-945429 (BIOLOGICAL), Placebo matching with BMS-945429 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01545050?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01545050's enrollment target sits among peer trials
72 925th of 2000 higher than 1,065 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia